PE20050755A1 - Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina - Google Patents

Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina

Info

Publication number
PE20050755A1
PE20050755A1 PE2004000963A PE2004000963A PE20050755A1 PE 20050755 A1 PE20050755 A1 PE 20050755A1 PE 2004000963 A PE2004000963 A PE 2004000963A PE 2004000963 A PE2004000963 A PE 2004000963A PE 20050755 A1 PE20050755 A1 PE 20050755A1
Authority
PE
Peru
Prior art keywords
composition
mycophenolic acid
rapamycin
multiparticles
combination
Prior art date
Application number
PE2004000963A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Becker
Carsten Burger
Gilles Feutren
Patrice Guitard
Andrea Kramer
Nicoletta Loggia
Christian-Peter Luftensteiner
Jorg Ogorka
Harald Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20050755A1 publication Critical patent/PE20050755A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2004000963A 2003-10-03 2004-10-01 Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina PE20050755A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds

Publications (1)

Publication Number Publication Date
PE20050755A1 true PE20050755A1 (es) 2005-11-28

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000963A PE20050755A1 (es) 2003-10-03 2004-10-01 Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina

Country Status (11)

Country Link
US (1) US20070036857A1 (https=)
EP (1) EP1670437A1 (https=)
JP (1) JP2007507458A (https=)
AR (1) AR045957A1 (https=)
AU (1) AU2004280078B2 (https=)
BR (1) BRPI0414864A (https=)
CA (1) CA2538099A1 (https=)
MX (1) MXPA06003646A (https=)
PE (1) PE20050755A1 (https=)
TW (1) TW200520759A (https=)
WO (1) WO2005034916A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
CN103330694A (zh) * 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
KR20100126465A (ko) * 2008-03-05 2010-12-01 파나세아 바이오테크 리미티드 미코페놀레이트를 포함하는 변형 방출 제약 조성물 및 그것의 방법
KR20120103431A (ko) * 2009-06-25 2012-09-19 대니스코 에이/에스 단백질
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
JP6368242B2 (ja) * 2011-10-06 2018-08-01 ノバルティス アーゲー 40−o−(2−ヒドロキシ)エチル−ラパマイシンを含む医薬組成物
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ,インコーポレイテッド ピロカルピンの医薬製剤
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事(everolimus)之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
WO2018170022A2 (en) * 2017-03-13 2018-09-20 Okava Pharmaceuticals, Inc. Methods and compositions for delivering mycophenolic acid active agents to non-human mammals
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
AU2022422597A1 (en) * 2021-12-23 2024-07-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
EP4526679A1 (en) * 2022-05-16 2025-03-26 Mayo Foundation for Medical Education and Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
CZ301771B6 (cs) * 1993-10-01 2010-06-16 Syntex (U.S.A.) Llc. Farmaceutický prostredek ve forme suchého granulátu obsahující mofetil mykofenolát nebo kyselinu mykofenolovou a zpusob jeho prípravy
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
CN1233169A (zh) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 一种粉末状制剂的制备工艺
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2002544167A (ja) * 1999-05-10 2002-12-24 ノバルティス アクチエンゲゼルシャフト 有機化合物
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
TW200306826A (en) * 2002-01-10 2003-12-01 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
US8163726B2 (en) * 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
US20040105778A1 (en) * 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BRPI0414864A (pt) 2006-11-28
AU2004280078B2 (en) 2008-08-07
AR045957A1 (es) 2005-11-16
CA2538099A1 (en) 2005-04-21
TW200520759A (en) 2005-07-01
US20070036857A1 (en) 2007-02-15
AU2004280078A1 (en) 2005-04-21
WO2005034916A1 (en) 2005-04-21
JP2007507458A (ja) 2007-03-29
MXPA06003646A (es) 2006-06-05
EP1670437A1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
PE20050755A1 (es) Composicion farmaceutica que comprende multiparticulas de acido micofenolico o micofenolato de sodio y combinacion de la composicion con rapamicina
MX2009004439A (es) Composicion de ibuprofeno.
RU2011138101A (ru) Фармацевтическая композиция, проявляющая противовоспалительные свойства
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR033711A1 (es) Composiciones farmaceuticas
BR0210139A (pt) Composições farmacêuticas
ES2165833T1 (es) Composicion farmaceutica revestida enterica y procedimiento de fabricacion.
MX2011013539A (es) Tabletas de farmaco solidas para dispositivos implantables para administrar farmacos.
AR026745A1 (es) Composiciones de eplerenona nanoparticulada
DK1480624T3 (da) Farmaceutisk tablet
CY1105559T1 (el) Φαρμακευτικες συνθεσεις του tegaserod
JP2009537554A5 (https=)
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
CR9632A (es) Tableta que contiene un ingrediente dificilmente soluble
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
HRP20110162A8 (hr) Spojevi koji sadrže amlodipin i bisoprolol
EP2234598C0 (fr) Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
MX2009003169A (es) Derivados de sulfonamida.
BRPI0412364A (pt) composição farmacêutica sólida, compreendendo amisulpride
CO5640071A2 (es) Composiciones farmaceuticas de atorvastatina
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler
DE60206940D1 (de) Pektin und ascorbinsäure enthaltende zusammensetzungen

Legal Events

Date Code Title Description
FX Voluntary withdrawal